Florida International University

FIU Digital Commons
Department of Biostatistics Faculty
Publications

Robert Stempel College of Public Health &
Social Work

10-1-2022

Impact of COVID-19 on Intracranial Meningioma Resection:
Results from California State Inpatient Database
Muni Rubens
Baptist Health South Florida

Anshul Saxena
Baptist Health South Florida

Venkataraghavan Ramamoorthy
Baptist Health South Florida

Md Ashfaq Ahmed
Baptist Health South Florida

Zhenwei Zhang
Baptist Health South Florida

See next page for additional authors

Follow this and additional works at: https://digitalcommons.fiu.edu/biostatistics_fac

Recommended Citation
Rubens, Muni; Saxena, Anshul; Ramamoorthy, Venkataraghavan; Ahmed, Md Ashfaq; Zhang, Zhenwei;
McGranaghan, Peter; Veledar, Emir; and McDermott, Michael, "Impact of COVID-19 on Intracranial
Meningioma Resection: Results from California State Inpatient Database" (2022). Department of
Biostatistics Faculty Publications. 51.
https://digitalcommons.fiu.edu/biostatistics_fac/51

This work is brought to you for free and open access by the Robert Stempel College of Public Health & Social Work
at FIU Digital Commons. It has been accepted for inclusion in Department of Biostatistics Faculty Publications by
an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

Authors
Muni Rubens, Anshul Saxena, Venkataraghavan Ramamoorthy, Md Ashfaq Ahmed, Zhenwei Zhang, Peter
McGranaghan, Emir Veledar, and Michael McDermott

This article is available at FIU Digital Commons: https://digitalcommons.fiu.edu/biostatistics_fac/51

cancers
Article

Impact of COVID-19 on Intracranial Meningioma Resection:
Results from California State Inpatient Database
Muni Rubens 1 , Anshul Saxena 2,3 , Venkataraghavan Ramamoorthy 2 , Md Ashfaq Ahmed 2 , Zhenwei Zhang 2 ,
Peter McGranaghan 1,4, * , Emir Veledar 2,3 and Michael McDermott 3,5, *
1
2
3

4

5

*

Citation: Rubens, M.; Saxena, A.;
Ramamoorthy, V.; Ahmed, M.A.;
Zhang, Z.; McGranaghan, P.;
Veledar, E.; McDermott, M. Impact of
COVID-19 on Intracranial
Meningioma Resection: Results from
California State Inpatient Database.
Cancers 2022, 14, 4785. https://
doi.org/10.3390/cancers14194785
Academic Editor: Samuel C. Mok
Received: 11 July 2022
Accepted: 26 September 2022
Published: 30 September 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.

Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
Center for Advanced Analytics, Baptist Health South Florida, Miami, FL 33143, USA
Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th St.,
Miami, FL 33199, USA
Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin, Corporate Member of
Freie Universität Berlin and Humboldt Universität zu Berlin, Augustenburger Platz 1, 10117 Berlin, Germany
Miami Neuroscience Institute, Baptist Health South Florida, 8950 N Kendall Dr. Suite 407W,
Miami, FL 33176, USA
Correspondence: peter.mcgranaghan@charite.de (P.M.); mwmcd@baptisthealth.net (M.M.);
Tel.: +49-30-450-50 (P.M.); +1-786-596-3876 (M.M.)

Simple Summary: All fields of healthcare were adversely affected by the COVID-19 pandemic. In
this study, we sought to understand the effects of COVID-19 on hospitalizations for intracranial
meningioma resection using a large database. We compared hospitalization rates as well as hospital
outcomes such as Clavien–Dindo grade IV complications, in-hospital mortality, and prolonged length
of stay for intracranial meningioma resection during 2019 and 2020. Our findings showed that though
hospitalization rates decreased slightly during the COVID-19 pandemic, hospital outcomes were not
adversely affected. The findings of our study show that with adequate planning and preparations,
better hospital outcomes could be sustained even during healthcare emergencies such as COVID-19
pandemic. Our findings assure that neurosurgery practice in the US ensured the best quality of care
to their patients even during COVID-19 pandemic.
Abstract: Purpose: To assess the effects of COVID-19 on hospitalizations for intracranial meningioma
resection using a large database. Methods: We conducted a retrospective analysis of the California
State Inpatient Database (SID) 2019 and 2020. All adult (18 years or older) hospitalizations were
included for the analysis. The primary outcomes were trends in hospitalization for intracranial
meningioma resection between 2019 and 2020. Secondary outcomes were Clavien–Dindo grade IV
complications, in-hospital mortality, and prolonged length of stay, which was defined as length of
stay ≥75 percentile. Results: There were 3,173,333 and 2,866,161 hospitalizations in 2019 and 2020,
respectively (relative decrease, 9.7%), of which 921 and 788 underwent intracranial meningioma
resection (relative decrease, 14.4%). In 2020, there were 94,114 admissions for COVID-19 treatment.
Logistic regression analysis showed that year in which intracranial meningioma resection was
performed did not show significant association with Clavien–Dindo grade IV complications and
in-hospital mortality (OR, 1.23, 95% CI: 0.78–1.94) and prolonged length of stay (OR, 1.05, 95% CI:
0.84–1.32). Conclusion: Our findings show that neurosurgery practice in the US successfully adapted
to the unforeseen challenges posed by COVD-19 and ensured the best quality of care to the patients.
Keywords: coronavirus; mortality; hospitalization; intracranial meningioma resection; morbidity
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1. Introduction
All fields of healthcare have been severely affected by the COVID-19 pandemic. Neurosurgery is no exception, and elective surgeries have been extensively affected resulting in
significantly lower admission rates, and postponements or even cancellations of surgical
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procedures [1,2]. This was due to the diversion of both healthcare resources and personnel
for COVID-19 management, so that both staff and equipment could be directed towards
COVID-19 related critical care needs [3,4]. The implementation of control measures such as
isolation and quarantine could have additionally decreased the admission rates of neurosurgical cases [5,6]. In addition, many patients opted to willfully delay treatment for the fear
of COVID-19 contraction during hospital encounters [7]. Many healthcare providers have
also experienced unforeseen challenges such as working in fields beyond their expertise,
managing cases with scarce resources, overcoming ethical issues, and risking their own
lives to COVID-19 [8–11].
Intracranial meningiomas are the most common type of benign primary intracranial
tumors [12]. They represent almost 37% of all primary central nervous system tumors and
50% of all benign brain tumors [12]. The majority of them are asymptomatic and are often
detected as incidental findings on magnetic resonance imaging [13]. During the period 2004
to 2017, the incidence of meningioma showed increasing trends. However, after this period,
the incidence plateaued and decreased [14]. Interventions are required when these tumors
grow in size within a short period of time and become symptomatic [15]. Management of
meningioma is primarily surgical resection and aims towards maximal or complete removal
of tumor and its dural tail [16,17]. These procedures are usually performed electively and
were affected by the COVID-19 pandemic.
In this study, we intended to understand the effects of COVID-19 on hospitalizations
for intracranial meningioma resection using a large database. Specifically, we compared
trends in monthly hospitalization rates for intracranial meningioma resection between
2019 and 2020. In addition, we also compared trends monthly hospitalization rates for
intracranial meningioma resection and COVID-19 hospitalizations in 2020. Furthermore,
we explored whether there were differences in adverse in-hospital outcomes after intracranial meningioma resection between the two years. The results of our study could provide
a detailed understanding of the effects of COVID-19 on intracranial meningioma resection in California and could give population-level estimates that could be useful to the
healthcare system.
2. Materials and Methods
2.1. Study Design and Data Source
The current study was a retrospective analysis of data retrieved from the California
State Inpatient Database (SID) gathered during 2019 and 2020. The SID was developed by
the Agency for Healthcare Research and Quality (AHRQ) for collecting statewide inpatient
clinical data [18]. SID has data from patients admitted to the participating hospitals within
the state [18]. Every year, discharge data from >90% of patients admitted to the participating
hospitals are collected and stored by the SID. We used the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guideline for assuring the quality of the
study [19].
2.2. Study Population
All adult (18 years or older) hospitalizations for intracranial meningioma resection
that occurred during 2019 and 2020 were included for the analysis. To identify these
hospitalizations, we used the International Classification of Diseases, Tenth Revision,
Clinical Modification (ICD-10-CM) diagnosis code D32.0 for benign neoplasms of the
cerebral meninges, and procedural codes 00510ZZ, 00B10ZZ, 00C10ZZ, and 00D10ZZ for
intracranial meningioma resection.
2.3. Study Variables and Outcomes
The primary outcomes of the study were trends in hospitalization for intracranial
meningioma resection between 2019 and 2020. Secondary outcomes were Clavien–Dindo
grade IV complications, in-hospital mortality, and prolonged length of stay. Prolonged
length of stay was defined as length of stay ≥75 percentile for the entire population. Clavien–
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Dindo grade IV complications include life-threatening complications due to dysfunction
one or more organ systems and requiring management in intensive care units [20]. The
Clavien–Dindo grade IV complications include components such as severe sepsis or septic
shock, acute renal failure requiring hemodialysis, pulmonary embolism, acute myocardial
infarction, cardiac arrest requiring cardiopulmonary resuscitation, prolonged mechanical ventilation, and unplanned intubation or re-intubation for managing postoperative
respiratory failure. We identified these components using ICD-10 codes (Supplementary
Table S1). The Clavien–Dindo grade IV complications have been previously used in studies
using administrative data [21–23]. Other variables included age, sex, race, insurance status,
clinical risk profile, and Elixhauser comorbidity index.
2.4. Statistical Analysis
Descriptive statistics were used to understand the differences in demographic and clinical risk profile between hospitalization for intracranial meningioma resection that occurred
during 2019 and 2020. Categorical variables were described as frequencies and percentages
and compared using chi-square test. Monthly trends in hospitalization for intracranial
meningioma resection between 2019 and 2020 and COVID-19 hospitalizations during 2020
were calculated and graphically plotted against one another. Logistic regressions were
used to find the differences in adverse clinical outcomes such as Clavien–Dindo grade IV
complications and in-hospital mortality, and prolonged length of stay during 2019 and
2020. In our models, we adjusted for covariates such as age, sex, race, insurance status, and
clinical risk profiles such as hypertension, diabetes mellitus, obesity, coagulation disorder,
peripheral vascular disease, liver disease, chronic renal failure, alcohol abuse, and drug
abuse. Sensitivity analysis was done among hospitalization of older adults aged 65 years
and above. In this analysis we used logistic regressions to find the differences in Clavien–
Dindo grade IV complications and in-hospital mortality during 2019 and 2020. Statistical
significance was set at p < 0.05 and all tests were two-sided. All statistical analyses were
conducted using SAS, version 9.4 (SAS Inc., Cary, NC, USA).
3. Results
There were 3,173,333 and 2,866,161 hospitalizations in 2019 and 2020, respectively
(relative decrease, 9.7%). Among these hospitalizations, 921 and 788 underwent intracranial
meningioma resection in 2019 and 2020, respectively (relative decrease, 14.4%). Among
all hospitalizations in 2020, there were 94,114 admissions for COVID-19 treatment. Comparison of demographic and clinical characteristics of hospitalizations for intracranial
meningioma resection that occurred in 2019 and 2020 showed that for both of the years
the majority of the patients were in the age group 45–64 years (45.2% versus 43.9%) and
majority were females (70.2% versus 69.5%). During both years, the majority of the hospitalizations occurred among Whites (51.0% versus 47.6%), followed by Hispanics (22.6% versus
23.9%), Asian or Pacific Islander and Native American (14.1% versus 15.3%), and Blacks
(6.7% versus 5.4%). Insurance status across both the years showed that majority had private
insurance coverages (42.1% versus 41.6%), followed by Medicare (38.4% versus 38.2%),
and Medicaid (15.3% versus 17.3%). The most common comorbidity was hypertension
(51.2% versus 51.4%), followed by obesity (19.7% versus 19.4%), diabetes mellitus (10.0%
versus 10.0%). Majority had Elixhauser comorbidity index values of 1 or 2 during both
years (46.3% versus 43.7%). None of the demographic and clinical characteristics differed
between 2019 and 2020. Table 1 shows the demographic and clinical characteristics of
hospitalizations for intracranial meningioma resection during 2019 and 2020.
A comparison of clinical outcomes of hospitalizations for intracranial meningioma
resection between 2019 and 2020 showed that Clavien–Dindo grade IV complications such
as severe sepsis or septic shock (1.4% versus 1.6%, p = 0.688), prolonged requirement of
mechanical ventilation (3.3% versus 4.3%, p = 0.251), and grade IV complication (4.5%
versus 5.3%, p = 0.399) did not differ significantly across the two years. Likewise, prolonged
length of stay (27.0% versus 27.9%, p = 0.683) did not differ significantly between 2019 and

Cancers 2022, 14, 4785

4 of 11

2020. Table 2 shows the clinical outcomes of hospitalizations for intracranial meningioma
resection during 2019 and 2020.
Table 1. Demographic and clinical characteristics of hospitalizations for intracranial meningioma
resection during 2019 and 2020.
2019
n = 921 (53.9%)

Characteristic

2020
n = 788 (46.1%)

Age, n (%)

p Value
0.858

18–44 years

139 (15.1%)

124 (15.7%)

45–64 years

416 (45.2%)

346 (43.9%)

≥65 years

366 (39.7%)

318 (40.4%)

Sex, n (%)

0.750

Male

274 (29.8%)

240 (30.5%)

Female

647 (70.2%)

548 (69.5%)

Race/ethnicity, n (%)

0.216

White

459 (51.0%)

372 (47.6%)

Black

60 (6.7%)

42 (5.4%)

Hispanic

203 (22.6%)

187 (23.9%)

Asian or Pacific Islander and Native American

127 (14.1%)

120 (15.3%)

Other

51 (5.7%)

61 (7.8%)

Insurance status, n (%)

0.427

Medicare

354 (38.4%)

301 (38.2%)

Medicaid

141 (15.3%)

136 (17.3%)

Private insurance

388 (42.1%)

327 (41.6%)

Other

38 (4.1%)

23 (2.9%)

Clinical risk profile, n (%)
Hypertension

472 (51.2%)

405 (51.4%)

0.951

Diabetes mellitus

92 (10.0%)

79 (10.0%)

0.980

Obesity

181 (19.7%)

153 (19.4%)

0.902

Coagulation disorder

50 (5.4%)

41 (5.2%)

0.835

Peripheral vascular disease

47 (5.1%)

43 (5.5%)

0.744

Liver disease

17 (1.8%)

26 (3.3%)

0.055

Chronic renal failure

53 (5.8%)

51 (6.5%)

0.536

Alcohol abuse

13 (1.4%)

11 (1.3%)

0.798

Drug abuse

27 (2.9%)

16 (2.0%)

0.235

Elixhauser comorbidity index, n (%)

0.482

0

197 (21.4%)

169 (21.4%)

1 or 2

426 (46.3%)

344 (43.7%)

≥3

298 (32.4%)

275 (34.9%)

Trends of hospitalizations for intracranial meningioma resection during 2019 and 2020
showed that the rates of these hospitalizations were generally lower in 2020, except for
February, May, and November. Trends of hospitalizations for intracranial meningioma
resection during 2020 showed an unusual dip during April, which also corresponded with
a spike in COVID-19 hospitalizations. Similarly, the decrease observed during July 2020
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corresponds with the spike in COVID-19 hospitalizations. The rates of hospitalizations
started to increase from August to October, corresponding with decreases in COVID-19
hospitalizations. Eventually, there was a steep decline in hospitalizations from November
to December, corresponding with an exponential increase in COVID-19 hospitalizations.
Cancers 2022, 14, x FOR PEER REVIEW
Figure 1 shows the trends in hospitalizations for intracranial meningioma resection during6 of 12
2019 and 2020 and COVID-19 hospitalizations during 2020.

Figure 1. Trends in hospitalizations for intracranial meningioma resection during 2019 and 2020 (A)

Figure 1. Trends in hospitalizations for intracranial meningioma resection during 2019 and 2020 (A)
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2020
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Cancers 2022, 14, 4785

6 of 11

Table 2. Clinical outcomes of hospitalizations for intracranial meningioma resection during 2019
and 2020.
2019
n = 1165 (66.8%)

2020
n = 575 (33.2%)

p Value

Severe sepsis or septic shock

13 (1.4%)

13 (1.6%)

0.688

Acute renal failure requiring dialysis

NR

NR

---

Pulmonary embolism

NR

NR

---

Acute myocardial infarction or cardiac arrest
requiring cardiopulmonary resuscitation

NR

NR

---

Prolonged requirement of
mechanical ventilation

30 (3.3%)

34 (4.3%)

0.251

Unplanned intubation/reintubation

NR

NR

---

Any grade IV complication

41 (4.5%)

42 (5.3%)

0.399

In-hospital mortality

NR

12 (1.5%)

---

Prolonged length of stay, n (%)

249 (27.0%)

220 (27.9%)

0.683

Characteristic
Clavien–Dindo grade IV complications

Note: NR is not reported to comply with Healthcare Cost and Utilization Project data use agreement guideline of
not to report tabulated data in a cell size ≤ 10 to protect individual identification.

Table 3. Factors associated with Clavien–Dindo grade IV complications and in-hospital mortality.
Characteristic

Odds Ratio (95% CI)

Year
2019

Reference

2020

1.23 (0.78–1.94)

Age
18–44 years

Reference

45–64 years

1.61 (0.73–3.54)

≥65 years

1.61 (0.58–4.51)

Sex
Male

Reference

Female

0.79 (0.48–1.28)

Race
White

Reference

Black

3.56 (1.65–7.65)

Hispanic

1.57 (0.84–2.95)

Asian or Pacific Islander and Native American

1.92 (0.99–3.74)

Other

2.06 (0.90–4.72)

Insurance status
Medicare

Reference

Medicaid

1.51 (0.64–3.59)

Private insurance

0.77 (0.34–1.76)

Other

1.49 (0.45–4.93)

Hypertension

0.81 (0.48–1.37)

Diabetes mellitus

0.56 (0.21–1.48)
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Table 3. Cont.
Characteristic

Odds Ratio (95% CI)

Obesity

1.03 (0.57–1.86)

Coagulation disorder

5.22 (2.82–9.67)

Peripheral vascular disease

0.85 (0.33–2.15)

Liver disease

1.39 (0.43–4.50)

Chronic renal failure

5.52 (2.84–10.76)

Alcohol abuse

1.11 (0.22–5.53)

Drug abuse

2.81 (0.99–7.96)

Table 4. Factors associated with prolonged length of stay.
Characteristic

Odds Ratio (95% CI)

Year
2019

Reference

2020

1.05 (0.84–1.32)

Age
18–44 years

Reference

45–64 years

1.25 (0.87–1.80)

≥65 years

1.29 (0.79–2.11)

Sex
Male

Reference

Female

0.80 (0.62–1.02)

Race
White

Reference

Black

1.21 (0.78–1.88)

Hispanic

1.62 (0.42–1.93)

Asian or Pacific Islander and Native American

1.03 (0.54–1.98)

Other

1.19 (0.89–1.76)

Insurance status
Medicare

Reference

Medicaid

1.21 (0.78–1.88)

Private insurance

0.62 (0.42–0.93)

Other

1.03 (0.54–1.98)

Hypertension

1.59 (1.23–2.06)

Diabetes mellitus

0.65 (0.43–0.97)

Obesity

0.95 (0.71–1.27)

Coagulation disorder

4.24 (2.67–6.73)

Peripheral vascular disease

0.81 (0.50–1.33)

Liver disease

1.29 (0.64–2.60)

Chronic renal failure

1.85 (1.19–2.88)

Alcohol abuse

1.73 (0.71–4.24)

Drug abuse

1.03 (0.56–1.88)
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Sensitivity analysis done among hospitalizations ≥65 years showed that year was
not significantly associated with Clavien–Dindo grade IV complications and in-hospital
mortality (OR, 1.27, 95% CI: 0.64–2.50). Supplementary Table S2 shows the odds ratios for
factors associated with Clavien–Dindo grade IV complications and in-hospital mortality
among hospitalizations ≥65 years.
4. Discussion
To the best of our knowledge, this is the first study that explored the impact of COVID-19
hospitalizations for intracranial meningioma resection. Using California SID, we found
that hospitalizations for intracranial meningioma resection were in general lower during 2020, compared to 2019. However, there were no significant differences in adverse
clinical outcomes across the years. We found that variations in hospitalizations for intracranial meningioma resection during 2020 corresponded with the fluctuations in rates of
COVID-19 hospitalizations.
The decrease in hospitalizations for resection of intracranial meningiomas in our study
is consistent with observations in other studies which show that a number of COVID-19
related factors could be responsible for these results [24–26]. The majority of these admissions could have been delayed because people were scared of contracting COVID-19
and were willing to postpone them [7,27,28]. COVID-19 measures such as shelter-in-place
and substantial prioritization of healthcare resources for managing COVID-19 could have
further decreased healthcare delivery for conditions other than COVID-19 [3,29]. The
Centers for Medicare & Medicaid Services and US Surgeon General recommended urgent
ban and postponing of all elective surgeries in the US during March 2020. Studies have also
shown that the rates of neurosurgeries were substantially affected by COVID-19 pandemic.
For example, in a study among two academic neurosurgery centers in New Orleans, in
2020, there was a 34% decrease in monthly neurosurgical volume [30]. Similarly, a study
done at an academic neurosurgery department reported that admission rates for neurosurgeries decreased by 69% during COVID-19 pandemic [31]. In addition, the COVID-19
pandemic has caused considerable disruption to the production and supply chains as well
as trading and transportation routes [32,33]. This could have precipitated shortages of
required logistics for delivering these procedures and deliberate postponements.
In our study, the rates of hospitalizations for resection of intracranial meningiomas
substantially decreased during April 2020. Similar decreases were also reported in other
studies during the initial spike of the pandemic. For example, in a study done among
8 neurosurgical training programs, the mean number of cases decreased by 49% during
April 2020 [34]. Similarly, a study performed in a neurosurgery department at the Johns
Hopkins University School of Medicine reported 45% decline in inpatient census during
the same period [31]. Elective operations were compulsorily prohibited in some institutions
during March and April when the pandemic was at its peak [30,31]. Reallocation of
operating rooms for accommodating COVID-19 assigned care areas could have precipitated
these findings [30]. In addition, factors such as cancellation of events and stay-at-home
mandate issued by the government of California in March 2020 could have caused the
substantial decline observed in our study [25]. Subsequently, the reopening plans proposed
by the governor of California was followed by a gradual increase in the number of these
hospitalizations until November 2020, when it exceeded the pre-COVID-19 levels [35].
Reintroduction of COVID-19 prevention measures during November and December, when
the states experienced a raging wave of the pandemic was followed by severe plummeting
of hospitalizations for resection of intracranial meningiomas observed during the end
of 2020.
We found that in-hospital clinical outcomes following intracranial meningioma resection such as Clavien–Dindo grade IV complications and in-hospital mortality and
prolonged length of stay were not different between 2019 and 2020. Clavien–Dindo grade
IV complications include single or multiple organ system failures requiring intensive care
unit admissions and interventions [20]. Similar findings were also observed in previous
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studies where COVID-19 did not have significant impact on adverse outcomes such as
mortality and prolonged length of stay as well as perioperative complications [30,31,36].
These findings show that although the volume of hospitalizations for intracranial meningioma resection have decreased due to diversion of resources for managing the pandemic,
healthcare providers have strived to provide the highest quality of care.
We also found that Clavien–Dindo grade IV complications and in-hospital mortality
were significantly higher among Blacks, indicating racial disparities in in-hospital outcomes following intracranial meningioma resection. Previous studies have shown that
Black patients had significantly worse outcomes following management for intracranial
meningioma. For example, a study done by Anzalone et al. using surveillance, epidemiology, and end results (SEER) database showed that Black patients had the worst disease
specific and overall survival rates at 5 years, compared to other races [37]. A systematic
review that included 55 studies showed that in general Black patients had higher rates of
complications and in-hospital mortality following neurosurgical treatments for intracranial
tumors [38]. Understanding the reasons for these disparities and trying to overcome them
through effective interventions could significantly help in alleviating them and achieving
equity in healthcare. In addition, we found that comorbidities such as chronic renal failure
was associated with Clavien–Dindo grade IV complications and in-hospital mortality, and
hypertension, coagulation disorder, and chronic renal failure with prolonged length of
stay following hospitalization for intracranial meningioma resection. These comorbidities
should be adequately scrutinized and controlled before planning for surgical treatment for
this condition. Such measures could significantly improve hospital outcomes and quality
of life among meningioma patients.
Strengths and Limitations
We used California SID for our analysis. California had the largest number of COVID-19
cases within the US. Therefore, we could accurately estimate the impact of COVID-19 on
relatively rare hospitalizations such as those for intracranial meningioma resection. In
addition, due to the larger sample size, our results have greater external validity.
One of the main limitations of this study was that we used an administrative database.
All variables in this study were retrieved from billing codes assigned to the conditions and
procedures following patients’ discharge. There could be some inaccuracies during coding,
leading to misclassification bias. These inconsistencies could have affected our findings. The
results are limited to the duration of hospitalization because SID does not have information
prior to or after hospitalization. Therefore, the complications that developed after discharge
could not be ascertained. SID does not have information on grading and staging of
meningioma, or other specifics such as tumor size, location, tumor extension, extent of
extraction, surgical methods, and other non-surgical managements such as radiotherapy
and embolization. Some meningioma pathologies require urgent hospitalization. However,
we could not ascertain these pathologies because SID is an administrative database. In
addition, provider details such as experience and expertise of the neurosurgeon, and
surgical techniques used at different hospitals were not available. The availability of these
important cofounders could have substantially improved our estimates.
5. Conclusions
Our study showed that hospitalizations for intracranial meningioma resection were
generally lower during 2020, compared to pre-COVID-19 levels. There were fluctuations
in hospitalization trends which corresponded with changes in COVID-19 hospitalizations.
Despite additional burden on healthcare systems due to COVID-19 pandemic, there were no
significant differences in adverse clinical outcomes. These findings indicate that healthcare
providers strived to deliver optimal levels of care in spite of the challenges posed by the
pandemic. These findings also assure that neurosurgery practice in the US successfully
adapted to these unforeseen challenges and ensured the best quality of care to their patients.
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